0001333277-18-000035.txt : 20180323 0001333277-18-000035.hdr.sgml : 20180323 20180323165649 ACCESSION NUMBER: 0001333277-18-000035 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180322 FILED AS OF DATE: 20180323 DATE AS OF CHANGE: 20180323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDFISCHER CARL CENTRAL INDEX KEY: 0001110780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 18710786 MAIL ADDRESS: STREET 1: 161 WEST 61ST STREET CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7999 GATEWAY BLVD STREET 2: SUITE 130 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7999 GATEWAY BLVD STREET 2: SUITE 130 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-03-22 0001042074 CymaBay Therapeutics, Inc. CBAY 0001110780 GOLDFISCHER CARL C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BOULEVARD NEWARK CA 94560 1 0 0 0 Common Stock 2018-03-22 4 M 0 9340 5.00 A 9340 D Common Stock 2018-03-22 4 M 0 5660 5.50 A 15000 D Common Stock 2018-03-22 4 S 0 15000 13.025 D 0 D Stock Option (right to buy) 5.00 2018-03-22 4 M 0 6470 0 D 2023-10-30 Common Stock 6470 0 D Stock Option (right to buy) 5.00 2018-03-22 4 M 0 2870 0 D 2024-01-05 Common Stock 2870 0 D Stock Option (right to buy) 5.50 2018-03-22 4 M 0 5660 0 D 2027-06-27 Common Stock 5660 9340 D The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.15, inclusive. The reporting person undertakes tp provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Fully vested. The option vests as to 1/12 of the underlying shares monthly from June 1, 2017. /s/ Sujal Shah, as attorney-in-fact 2018-03-23